Effects of a 1-year treatment with a low-dose combined oral contraceptive containing ethinyl estradiol and cyproterone acetate on glucose and insulin metabolism.
Adult; C-Peptide/analysis; Contraceptives, Oral, Combined/pharmacology; Cyproterone Acetate/pharmacology; Drug Combinations; Ethinyl Estradiol/pharmacology; Female; Glucose/metabolism; Glucose Tolerance Test; Humans; Insulin/metabolism/pharmacology; Metabolic Clearance Rate; OT - Biology; OT - Carbohydrate Metabolic Effects; OT - Contraception; OT - Contraceptive Methods; OT - Family Planning; OT - *Glucose Metabolism Effects; OT - *Metabolic Effects; OT - Oral Contraceptives; OT - *Oral Contraceptives, Combined; OT - *Oral Contraceptives, Low-dose; OT - Physiology; OT - *Prospective Studies; OT - Research Methodology; OT - *Research Report; OT - Studies
Abstract :
[en] OBJECTIVE: To study the effects of the slightly estrogen-dominant monophasic low-dose oral contraceptive (OC) Diane-35 (Schering AG, Berlin, Germany) (35 micrograms ethinyl estradiol [EE2] + 2 mg cyproterone acetate, a 17 alpha-hydroxyprogesterone derivative [17-OHP]) on glucose and insulin metabolism. DESIGN: Seven healthy young women were investigated by using the euglycemic hyperinsulinemic glucose clamp technique (insulin delivery rate = 100 mU/kg per hour for 120 minutes). This test was performed, after an overnight fast, during the last 7 days of a spontaneous cycle and within the last 5 days of pill intake during the sixth and twelfth cycle of a continuous treatment with Diane-35 in each subject. RESULTS: The three indexes measuring the insulin-induced glucose disposal during the clamp (glucose infusion rate, glucose metabolic clearance rate, and glucose infusion rate divided by plasma insulin plateau levels) were not significantly affected by Diane-35. In contrast, the metabolic clearance rate of the exogenous insulin infused during the clamp tended to be slightly increased with Diane-35 (significant after 6 but not after 12 cycles). CONCLUSION: These results suggest that a 1-year treatment with the OC Diane-35, which contains EE2 + a 17-OHP rather than a 19-nortestosterone derivative as the progestogen compound, does not significantly alter peripheral (presumably muscular) insulin sensitivity but slightly increases insulin (presumably hepatic) clearance.
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Jandrain, Bernard ; Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques
Humblet, Dominique ; Centre Hospitalier Universitaire de Liège - CHU > Ophtalmologie
Jaminet, C. B.
Gaspard, Ulysse ; Centre Hospitalier Universitaire de Liège - CHU > Gynécologie-Obstétrique
Lefebvre, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques
Language :
English
Title :
Effects of a 1-year treatment with a low-dose combined oral contraceptive containing ethinyl estradiol and cyproterone acetate on glucose and insulin metabolism.
U.J. Gaspard Metabolic effects of oral contraceptives Am J Obstet Gynecol 157 1987 1029 1041
U.J. Gaspard P.J. Lefébvre Clinical aspects of the relationship between oral contraceptives, abnormalities in carbohydrate metabolism, and the development of cardiovascular disease Am J Obstet Gynecol 163 1990 334 343
A.S. Luyckx U.J. Gaspard M.A. Romus F. Grigorescu P. De Meyts P.J. Lefebvre Carbohydrate metabolism in women who used oral contraceptives containing levonorgestrel or desogestrel: a 6-month prospective study Fertil Steril 45 1986 635 642
N. van der Vange H.J. Kloosterboer A.A. Haspels Effect of seven low-dose combined oral contraceptive preparations on carbohydrate metabolism Am J Obstet Gynecol 156 1987 918 922
W.N. Spellacy A.B. Ellingson J.C.M. Tsibris The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use Fertil Steril 51 1989 71 74
I.F. Godsland D. Crook R. Simpson T. Proudler C. Felton B. Lees The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism N Engl J Med 323 1990 1375 1381
P. Vexiau D. Vexiau-Robert I. Martineau N. Hardy J.M. Vilette J. Fiet Metabolic effect at six and twelve months of cyproterone acetate (2 mg) combined with ethinyl estradiol (35 μ g) in 31 patients Horm Metab Res 22 1990 241 245
B.J. Jandrain D.M.P. Humblet C.B. Jaminet A.J. Scheen U.J. Gaspard P.J. Lefèbvre Effects of ethinyl estradiol combined with desogestrel and cyproterone acetate on glucose tolerance and insulin response to an oral glucose load: A one-year randomized, prospective, comparative trial Am J Obstet Gynecol 163 1990 378 381
R.N. Bergman D.T. Finegood M. Ader Assessment of insulin sensitivity in vivo Endocr Rev 6 1985 45 86
S.O. Skouby O. Andersen N. Saurbrey C. Kühl Oral contraception and insulin sensitivity: in vivo assessment in normal women and women with previous gestational diabetes J Clin Endocrinol Metab 64 1987 519 523
G. Kasdorf R.K. Kalkhoff Prospective studies of insulin sensitivity in normal women receiving oral contraceptive agents J Clin Endocrinol Metab 66 1988 846 852
I.F. Godsland C. Walton C. Felton A. Proudler A. Patel V. Wynn Insulin resistance, secretion, and metabolism in users of oral contraceptives J Clin Endocrinol Metab 74 1992 64 70
J. Hammerstein J. Meckies I. Leo-Rossberg L. Moltz F. Zielske Use of cyproterone acetate in the treatment of acne, hirsutism and virilism J Steroid Biochem 6 1975 827 836
S. Aydinlik J. Kaufmann U. Lachnit-Fixson J. Lehnert Long-term therapy of signs of androgenisation with a low-dosed antiandrogen-oestrogen combination Clin Trials J 27 1990 392 402
M. Seed I.F. Godsland V. Wynn H.S. Jacobs The effects of cyproterone acetate and ethinyl oestradiol on carbohydrate metabolism Clin Endocrinol (Oxf) 21 1984 689 699
B. Jandrain A.J. Scheen Ph Henrivaux G. Paolisso A.S. Luyckx P.J. Lefebvre Insulin sensitivity and glucose tolerance during the menstrual cycle J. Vague P. Bjorntorp B. Guy-Grand M. Rebuffé-Scrive P. Vague Metabolic complications of human obesities 1985 Elsevier Science Publishers Amsterdam 241 247
National Diabetes Data Group Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance Diabetes 28 1979 1039 1057
R.A. DeFronzo J.D. Tobin R. Andres Glucose clamp technique: a method for quantifying insulin secretion and resistance Am J Physiol 232 1979 E214 E223
A.J. Scheen M. Castillo G. Paolisso B. Jandrain P.J. Lefèbvre Normal feedback inhibition of insulin secretion by insulin but reduced metabolic clearance rate of the hormone in obese subjects G. Ailhaud B. Guy-Grand M. Lafontan D. Ricquier Obesity in Europe 91 1992 John Libbey and Company Ltd London-Paris 201 205
C.N. Hales P.J. Randle Immunoassay of insulin with insulin-antibody precipitate Biochem J 88 1963 137 146
L.G. Heding Radioimmunological determination of human C-peptide in serum Diabetologia 11 1975 541 548
E. Ferrannini J. Wahren O.K. Faber P. Felig C. Binder R.A. DeFronzo Splanchnic and renal metabolism of insulin in human subjects: a dose-response study Am J Physiol 244 1983 E517 E527
G.O. Zerbe Randomization analysis of randomized blocks design extended to growth and response curves Commun Statist A8 1979 191 205
K.S. Polonsky A.H. Rubenstein C-peptide as a measure of the secretion and hepatic extraction of insulin Pittfalls and limitations. Diabetes 33 1984 486 494